{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:50:31Z","timestamp":1785408631589,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:04:04Z","timestamp":1758603844000},"page":"e110-e113.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4527-0500","authenticated-orcid":false,"given":"Julie","family":"Braish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-3362","authenticated-orcid":false,"given":"Wei-Ying","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2025.09.010_bib0001","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.010_bib0002","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.09.010_bib0003","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2025.09.010_bib0004","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.09.010_bib0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2025.09.010_bib0006","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.09.010_bib0007","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.09.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00707","article-title":"Philadelphia-like genetic rearrangements in adults with B-cell ALL: refractoriness to chemotherapy and response to tyrosine kinase inhibitor in ABL class rearrangements","volume":"7","author":"Senapati","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clml.2025.09.010_bib0009","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","article-title":"Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia","volume":"36","author":"Graux","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2025.09.010_bib0010","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.leu.2403357","article-title":"Amplification of the ABL gene in T-cell acute lymphoblastic leukemia","volume":"18","author":"Barber","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.09.010_bib0011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/gcc.20743","article-title":"ABL1 rearrangements in T-cell acute lymphoblastic leukemia","volume":"49","author":"Hagemeijer","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.09.010_bib0012","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2008.80","article-title":"Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.09.010_bib0013","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/leu.2008.318","article-title":"Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia","volume":"23","author":"Deenik","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.09.010_bib0014","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2025.09.010_bib0015","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1038\/bcj.2015.13","article-title":"Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia","volume":"5","author":"Collette","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2025.09.010_bib0016","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.3324\/haematol.2016.160531","article-title":"Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia","volume":"102","author":"Frech","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.09.010_bib0017","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.3324\/haematol.2015.139568","article-title":"Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia","volume":"101","author":"Perwein","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.09.010_bib0018","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study [Erratum in: Lancet Haematol. 2021;8(11):e789. 10.1016\/S2352-3026(21)00310-0]","volume":"8","author":"den Boer","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:52:32Z","timestamp":1768387952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025042156"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}